First Evaluation Switching From Ropivacaine to Highly Concentrated Bupivacaine in Intrathecal Mixtures for Cancer Pain.
Florent BienfaitSabrina Jubier-HamonValérie SeegersYves-Marie PluchonNathalie LebrecVirginie JaoulFrançois BoréThierry DelormeJulien RobertMartine BellangerJérémy SorrieulDenis DupoironPublished in: Neuromodulation : journal of the International Neuromodulation Society (2021)
Switching from ropivacaine to bupivacaine in IDDS appears more efficacious while remaining just as secure, and at lower cost.